Last updated: March 14, 2026
What is NDC 70954-0978?
NDC 70954-0978 refers to Remdesivir (Veklury), an antiviral treatment approved by the FDA for COVID-19. It gained prominence during the pandemic as a treatment option for hospitalized patients. The drug is produced by Gilead Sciences and includes intravenous formulations.
Market Overview
Current Market Landscape
- The initial surge in remdesivir demand corresponded with the COVID-19 pandemic onset in 2020.
- US government and private payers initially purchased large quantities under emergency use agreements.
- Commercial adoption transitioned into standard care, maintaining consistent demand.
Key Players
| Company |
Drug |
Market Share |
Production Capacity |
Key Marketing Strategies |
| Gilead Sciences |
Remdesivir (Veklury) |
100%* |
Estimated 10-20 million doses/year |
Government contracts, hospital supply contracts |
(Estimate based on US market share, as Gilead is sole producer of remdesivir.)
Regulatory Status
- FDA approval granted in October 2020.
- WHO recommends its use in severe COVID-19 cases.
- Expanded to include pediatric indications in certain settings.
Market Drivers
- Ongoing COVID-19 infection rates.
- Use in severe cases, especially in hospitals.
- Variants and new strains may affect treatment protocols, potentially increasing demand for antiviral agents like remdesivir.
Market Challenges
- Competition from emerging antiviral drugs: molnupiravir (Merck), Paxlovid (Pfizer).
- Pricing negotiations with payers.
- Emergence of alternative treatments and vaccines reducing hospitalized cases.
Forecasted Demand Dynamics
| Year |
Estimated Doses Needed |
Comments |
| 2023 |
8-12 million doses |
Stabilizing demand, driven by case severity and variant prevalence |
| 2024 |
6-10 million doses |
Potential decline if new therapeutics or vaccination rates rise |
| 2025 |
4-8 million doses |
Likely further decline if alternative treatments dominate |
Price Analysis and Projections
Current Pricing Structure
- List price per vial: approximately $390–$520 (as of 2022) [1].
- Typical treatment course: 6 doses over 5–10 days.
- Treatment cost: approximately $2,340–$3,120 per patient.
Contract and Negotiation Impact
- Prices are subject to negotiations with payers.
- Government and large hospital systems often secure negotiated discounts.
- Price variability exists based on procurement volume and contractual terms.
Historical Price Trends
- Initial emergency use prices: higher; offered directly by Gilead.
- Transition to commercial pricing stabilized around $390–$520 per vial.
- Price reductions seen with increased production capacity and competition.
Future Price Projections (2023–2025)
| Year |
Estimated Price Per Vial |
Notes |
| 2023 |
$350–$500 |
Slight reduction due to increased supply and negotiations |
| 2024 |
$330–$480 |
Competitive pressures increase, prices stabilize or decline |
| 2025 |
$300–$450 |
Possible further reductions with pipeline competition |
Market Exit and Patent Considerations
- No patent expiration currently; Gilead retains exclusivity.
- Patent challenges unlikely in the near term due to FDA approval status.
- Market entry of generics unlikely before 2030, given the current patent protections and manufacturing barriers.
Conclusion
The remdesivir market remains pricing stability, with moderate price declines expected through 2025 as competition and manufacturing efficiencies improve. Demand will be primarily driven by ongoing COVID-19 cases and treatment protocols, with demand volume likely to decrease over time.
Key Takeaways
- Gilead dominates the remdesivir market, with no significant generic competition.
- Current treatment costs range between $2,340 and $3,120 per patient.
- Price per vial is projected to decline gradually, reaching $300–$450 by 2025.
- Demand volume remains linked to COVID-19 case severity, with potential declines as new treatments and vaccines mature.
- Price negotiations and future competition will influence long-term market dynamics.
FAQs
Q1: Will remdesivir's price decrease significantly after patent expiry?
A1: Patent expiry is unlikely before 2030. Generic competition would typically bring substantial price reductions, but current patent protections prevent this.
Q2: What factors could cause demand for remdesivir to decline?
A2: The development of oral antiviral drugs, increased vaccination rates, and changes in COVID-19 hospitalization trends could reduce demand.
Q3: How do prices vary between government and private sector contracts?
A3: Government contracts often secure discounts, reducing procurement costs compared to list prices for private payers.
Q4: What is the impact of emerging COVID-19 variants on remdesivir demand?
A4: Variants that increase severe cases may sustain or boost demand, while milder strains could reduce it.
Q5: Are there any regulatory or policy conflicts affecting remdesivir’s market?
A5: No significant regulatory conflicts are anticipated. However, policy shifts favoring oral antivirals might influence its usage.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) product information. Retrieved from https://www.gilead.com
